Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
…
4 pages
1 file
Cardiomyopathy is an uncommon presentation in hyperthyroid patients. There are very few case reports of thyrotoxic cardiomyopathy. The mechanism due to which cardiomyopathy occurs in hyperthyroid patients is not very well understood. After extensive literature search, it was found that some of the mechanisms described which include genomic, non-genomic and direct action of Thyroid hormone on the cardiac muscle may cause cardiomyopathy. In this case report, a case of Multi-nodular goitre with cardiomyopathy is described.
International Journal of Scientific Reports
Hyperthyroidism significantly affects the hemodynamics of the cardiovascular system. It is associated with development of atrial fibrillation, high output cardiac failure, pulmonary hypertension and dilated cardiomyopathy (DCM). In this paper we report a case of thyrotoxicosis induced cardiomyopathy. She was a 54 year old woman who presented with cardiomegaly (dilatation of all four chambers of the heart) secondary to Graves’ disease. She was treated with anti-thyroid drugs, β Blockers and diuretic and her euthyroid status was restored in 6 weeks. A repeat echocardiogram done at this point of time showed normal cardiac function with normalization of ejection fraction. So this was a case of reversible thyrotoxic cardiomyopathy.
European Endocrinology
Thyroid hormones, mainly triiodothyronine, have genomic and non-genomic effects on cardiomyocytes related to the contractile function of the heart. Thyrotoxicosis, which is the set of signs and symptoms derived from the excess of circulating thyroid hormones, leads to increased cardiac output and decreased systemic vascular resistance, increasing the volume of circulating blood and causing systolic hypertension. In addition, the shortening of the refractory period of cardiomyocytes produces sinus tachycardia and atrial fibrillation. This leads to heart failure. Approximately 1% of patients with thyrotoxicosis develop thyrotoxic cardiomyopathy, a rare but potentially fatal form of dilated cardiomyopathy. Thyrotoxic cardiomyopathy represents a diagnosis of exclusion, and prompt identification is crucial as it is a reversible cause of heart failure, and heart function can be recovered after achieving a euthyroid state using antithyroid drugs. Radioactive iodine therapy and surgery are ...
Baylor University Medical Center Proceedings
Current Heart Failure Reports, 2008
The most recognizable features of hyperthyroidism are those that result from the effects of triiodothyronine (T 3 ) on the heart and cardiovascular system: decreased systemic vascular resistance and increased resting heart rate, left ventricular contractility, blood volume, and cardiac output. Although these measures of cardiac performance are enhanced in hyperthyroidism, the fi nding of clinical cardiac failure can be somewhat paradoxical. About 6% of thyrotoxic individuals develop symptoms of heart failure, but less than 1% develop dilated cardiomyopathy with impaired left ventricular systolic function. Heart failure resulting from thyrotoxicosis is due to a tachycardia-mediated mechanism leading to an increased level of cytosolic calcium during diastole with reduced ventricular contractility and diastolic dysfunction, often with tricuspid regurgitation. Pulmonary artery hypertension in thyrotoxicosis is gaining awareness as a cause of isolated right-sided heart failure. In both cases, older individuals are more likely to be affected. Treatment needs to be directed at management of the acute cardiovascular complications, control of the heart rate, and thyroid-specifi c therapy to restore a euthyroid state that will lead to resolution of the signs and symptoms of heart failure.
Endocrinology and Metabolism Clinics of North America, 1998
Gerontology & Geriatrics Studies, 2017
Case One Mrs. GC was a 49 years old Nigerian trader presenting with two weeks history of breathlessness, one week history of pedal swelling and four day history of cough. Her breathlessness started on exertion and was relieved by rest, there was associated poorly radiating dull central chest pain with no aggravating or relieving factor, there is associated orthopnea, paroxysmal nocturnal dyspnea and palpitation. Bilateral pedal swelling started a week prior to presentation it has been recurrent with polyuria and bilateral loin pain no dysuria, no nocturia, no frothiness of urine, no facial swelling that regresses as day goes by. Dry cough started four day prior to presentation with associated low grade fever, occasional polydipsia no polyphagia. She has been having chronic diarrhoea and weight loss for one year with human immunodeficiency virus test that is negative repeatedly. Diagnosed to have peptic ulcer disease two years ago, not a known hypertensive, diabetic or thyrotoxic patient. She is married to a 55 year old Nigerian clergyman with four children. She doesn't smoke or take alcohol. On examination she was cachectic, afebrile ,pale, slightly icteric, not cyanosed, no asterixis, bilateral pitting pedal oedema up to the knee, fine tremor present, World Health Organisation (WHO) stage ll goitre, measures 8cm x 4cm x1cm no eye signs. Cardiovascular examination showed pulse rate 120 beats/min, arterial wall thickened, irregularly irregular, locomotor brachialis,
Clinical Medicine Insights: Case Reports, 2013
The objective of this report is to present a case of Graves’ thyrotoxicosis-induced cardiomyopathy. This is a case of a 26 year old woman that presented with severe symptomatic congestive heart failure and was subsequently diagnosed with dilated cardiomyopathy secondary to Graves’ disease. Despite an initial left ventricular systolic ejection fraction of 20% on echocardiography, treatment with anti-thyroid agents led to rapid improvement of her clinical status and normalization of her ejection fraction. The proposed mechanisms underlying the development of systolic dysfunction in thyrotoxicosis are discussed and the literature on similar cases previously reported is highlighted. Cardiomyopathy should be considered even in young patients with Graves’ thyrotoxicosis.
Hyperthyroidism is a common metabolic disorder with many cardiovascular manifestations. In rare cases, untreated hyperthyroidism can lead to thyrotoxic cardiomyopathy with severe left ventricular (LV) dysfunction. This case report aims to discuss the pathogenesis of heart failure in hyperthyroidism and the available treatment options. A 51-year-old male with a past history of untreated hyperthyroidism presented to our hospital for the evaluation of shortness of breath and dysphagia. Workup revealed atrial flutter and severe biventricular dilated cardiomyopathy. Stabilization thyroidectomy was performed due to dysphagia, and treatment with oral antithyroid medications was initiated. The patient was discharged on synthroid and beta-blockers. Untreated hyperthyroidism can lead to biventricular failure even in the young. Untreated hyperthyroidism leads to significant mortality and morbidity. Untreated hyperthyroidism is associated with atrial fibrillation, heart failure, pulmonary hypertension (PH), and angina-like symptoms. Further studies should be done to evaluate the pathogenesis of Graves/Goiter hyperthyroidism and the least-invasive, safe, and definitive treatment options should be discovered. Current treatment options are limited and include medication that needs to be taken lifelong; they are associated with toxicity. Radioactive iodine ablation comes with the drawback of long-term replacement therapy. The last option is surgery, which is invasive and has its own complications.
Clinical Cardiology, 2000
The heart is an organ sensitive to the action of thyroid hormone, and measurable changes in cardiac performance are detected with small variations in thyroid hormone serum concentrations. Most patients with hyperthyroidism experience cardiovascular manifestations, and the most serious complications of hyperthyroidism occur as a result of cardiac involvement. Recent studies provide important insights into the molecular pathways that mediate the action of thyroid hormone on the heart and allow a better understanding of the mechanisms that underlie the hemodynamic and clinical manifestations of hyperthyroidism. Several cardiovascular conditions and drugs can interfere with thyroid hormone levels and may pose a difficulty in interpretation of laboratory data in patients with suspected thyroid heart disease. The focus of this report is a review of the current knowledge of thyroid hormone action on the heart and the clinical and hemodynamic laboratory findings as well as therapeutic management of patients with hyperthyroid heart disease.
Sociological Theory, 2009
América Latina en la crisis global Problemas y Desafíos, 2013
International Journal of Trade, Economics and Finance, 2013
Estudos do Quaternário, 2023
REMHU, Revista Interdisciplinar da Mobilidade Humana, 2023
Quick Calculations Absorption Cooling, 2021
Sleep and Breathing, 2015
Nasza Przeszłość
Quaderni Storici, 2013
arXiv (Cornell University), 2021
Biochemical and Biophysical Research Communications, 2008
アジア・アフリカの言語と言語学 (Asian and African languages and linguistics), 2017
Journal of Magnetism and Magnetic Materials, 1980
Revista Científica Gênero na Amazônia
Evolutionary Bioinformatics, 2012
Andragogi, 2022
Immunology Letters, 1997